Skip to content

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05095311
Enrollment
16
Registered
2021-10-27
Start date
2021-05-19
Completion date
2022-04-27
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise-induced Arterial Hypoxemia

Brief summary

Exercise-induced arterial hypoxemia (EIAH), a reduced amount of oxygen in the arterial blood during exercise, has been observed in otherwise healthy, highly-trained endurance athletes during exercise at sea level. The extent of the arterial deoxygenation may be influenced by a histamine-mediated inflammatory response at the pulmonary capillary-alveolar membrane limiting oxygen diffusion. Moreover, while EIAH has been routinely explored in running and cycling, swimming is understudied despite potential mechanistic avenues which may put swimmers at further risk for EIAH. The purpose of this study is threefold: 1) to determine whether highly-trained swimmers experience EIAH during submaximal and maximal exercise, 2) to determine the extent to which histamine release influences oxyhemoglobin saturation during swimming exercise, and 3) to determine whether cetirizine HCl (CH), an H1-receptor competitive inhibitor, can improve oxyhemoglobin saturation during submaximal and maximal swimming exercise. Twenty-four (12 men, 12 women) highly-trained swimmers will complete an intense swimming protocol to assess the histamine response to intense exercise. A subset with the highest histamine responses will participate in three additional sessions (placebo, NS, and CH conditions) which will include a swimming aerobic capacity test and 5-minutes of swimming at both 70 and 85% of their maximal oxygen uptake.

Detailed description

For the first testing session, participants will report to the Indiana University Human Performance Laboratory to complete a medical screening and, if willing, consent to the procedures of the study. The medical screening will include measurements of height, weight, resting heart rate, resting blood pressure, and resting pulmonary function along with a health history questionnaire. The second testing session consists of an assessment of risk factors for development of EIAH, specifically changes in blood biomarkers pre- and post-swimming exercise. Participants will report to the Counsilman-Billingsley Aquatics Center and complete an exercise protocol designed to elicit an inflammatory response. Venous blood draws will be performed to assess participants' pre-exercise complete blood count and pre- and post-intense exercise concentrations of plasma IL-1β, IL-8, plasma histamine, whole blood histamine, and histamine release. Measurements of hemoglobin concentration and hematocrit will also be performed pre- and post-exercise in order to correct biomarker concentrations for fluid loss during exercise. Swimmers of each sex that exhibit the largest histamine release will be selected for further study until at least four swimmers of each sex complete all three experimental trials. Twelve swimmers (n = 6 men, n = 6 women) will be selected for further trials. Those selected for further study will visit the Human Performance Laboratory on two occasions separated by at least 48 hours and no more than 60 days. Apart from receiving a placebo (PL) or drug treatment (cetirizine HCl, CH) prior to exercise, participants will perform identical protocols on each visit to the laboratory. Participants will report to the lab and consume either a placebo or CH pill, followed by a health history update questionnaire and their resting pulmonary function will be measured. Participants will then complete a self-selected warm-up that will be standardized across all testing sessions, followed by instrumentation. The exercise protocol beings with a progressive swimming test to maximum aerobic capacity (V̇O2max) in a swimming flume, followed by two constant load work bouts at approximately 70 and 85% of the previously recorded HRmax while peripheral capillary oxyhemoglobin saturation (SpO2) is continuously monitored. Participants will receive a 20-min break between each work bout. Drug treatments will be assigned in a double-blind, randomized crossover fashion such that each participant receives each treatment. Concentrations of plasma histamine, whole blood histamine, and histamine release will be assessed from pre- and post-exercise blood samples.

Interventions

DRUGCetirizine HCl

Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.

OTHERPlacebo

The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women * 18-35 years old * Current collegiate or professional swimmer * Currently training at least 300 minutes per week * Self-reported to be healthy

Exclusion criteria

* Not within defined age range * Current diagnosis of or using medication for: * Severe allergies * Asthma * Exercise-induced asthma * Exercise-induced bronchoconstriction * Pulmonary function test considered to be abnormal (defined as forced vital capacity (FVC) \<80% of predicted, forced expiratory volume in one second (FEV1) \<80% predicted, and/or FEV1/FVC ratio \>5% of the predicted ratio) * Hypertension during screening (systolic blood pressure \>139 or diastolic blood pressure \>89) * Current tobacco or electronic cigarette use or consistent use within the last 2 years * A contraindication for use of nedocromil sodium: * Previous adverse reaction to nedocromil sodium or a similar medication * Use of fast-acting, inhaled insulin * A contraindication for use of cetirizine HCl: * Previous adverse reaction to cetirizine HCl or a similar medication * Allergy to the food additives E218 or E216 * An intolerance to or inability to absorb some sugars, such as lactose or sorbitol * Liver or kidney failure * Epilepsy or similar condition * A condition that makes urinating difficult * Use of midodrine or ritonavir * Are pregnant or could possibly be pregnant by self-report * Subjects with current, irregular menstrual cycles (amenorrhea) or who had irregular menstruation patterns for greater than one year * People who answer 'yes' to any of the pre-participation screening questions on page one of the PAR-Q+ questionnaire.

Design outcomes

Primary

MeasureTime frameDescription
Peripheral Capillary Oxyhemoglobin SaturationIn the final minute of the aerobic capacity test and each of the two (70% and 85% of max) constant load trials in Visits 3 and 4 of the studySpO2 percentage measured via a standard bedside pulse oximetry unit

Countries

United States

Participant flow

Recruitment details

The recruitment period lasted from March 2021 through April 2022. Participants were connected to the investigators through their coach, and participants were asked to schedule a screening visit (Visit 1) if desired.

Pre-assignment details

The experimental arm of the study was limited to those participants who wanted to continue with the study and responded to correspondence from investigators.

Participants by arm

ArmCount
Experimental Group
This subset of 12 individuals will complete all experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents or 2) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion. Cetirizine HCl: Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise. Placebo: The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
4
Selection Pool
Twenty-four total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (6 men, 6 women) will be a subset of the initial 24. The other 12 participants will not take part in further study.
12
Total16

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up700

Baseline characteristics

CharacteristicExperimental GroupSelection PoolTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
4 Participants12 Participants16 Participants
Age, Continuous20.0 years
STANDARD_DEVIATION 1.8
20.1 years
STANDARD_DEVIATION 1.9
20.1 years
STANDARD_DEVIATION 1.8
Forced Expiratory Volume in 1 Second (FEV1)4.92 liters
STANDARD_DEVIATION 0.67
5.40 liters
STANDARD_DEVIATION 0.86
5.28 liters
STANDARD_DEVIATION 0.82
Forced Mid-Expiratory Flow (FEF25-75%)3.88 liters
STANDARD_DEVIATION 0.6
5.08 liters
STANDARD_DEVIATION 1.11
4.78 liters
STANDARD_DEVIATION 1.12
Forced Vital Capacity (FVC)6.76 liters
STANDARD_DEVIATION 0.91
6.87 liters
STANDARD_DEVIATION 1.17
6.85 liters
STANDARD_DEVIATION 1.09
Peak Expiratory Flow (PEF)10.14 liters per second
STANDARD_DEVIATION 1.75
9.21 liters per second
STANDARD_DEVIATION 1.29
9.45 liters per second
STANDARD_DEVIATION 1.42
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants12 Participants15 Participants
Region of Enrollment
United States
4 participants12 participants16 participants
Sex: Female, Male
Female
1 Participants6 Participants7 Participants
Sex: Female, Male
Male
3 Participants6 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 40 / 4
other
Total, other adverse events
0 / 160 / 40 / 4
serious
Total, serious adverse events
0 / 160 / 40 / 4

Outcome results

Primary

Peripheral Capillary Oxyhemoglobin Saturation

SpO2 percentage measured via a standard bedside pulse oximetry unit

Time frame: In the final minute of the aerobic capacity test and each of the two (70% and 85% of max) constant load trials in Visits 3 and 4 of the study

Population: These individuals are from the Experimental group.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboPeripheral Capillary Oxyhemoglobin SaturationAerobic capacity test96.8 percent hemoglobin saturationStandard Deviation 1.3
PlaceboPeripheral Capillary Oxyhemoglobin Saturation70% constant load98.2 percent hemoglobin saturationStandard Deviation 1.8
PlaceboPeripheral Capillary Oxyhemoglobin Saturation85% constant load98.8 percent hemoglobin saturationStandard Deviation 1.3
Cetirizine HClPeripheral Capillary Oxyhemoglobin SaturationAerobic capacity test98.0 percent hemoglobin saturationStandard Deviation 1.8
Cetirizine HClPeripheral Capillary Oxyhemoglobin Saturation70% constant load98.5 percent hemoglobin saturationStandard Deviation 1.1
Cetirizine HClPeripheral Capillary Oxyhemoglobin Saturation85% constant load97.9 percent hemoglobin saturationStandard Deviation 1.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026